Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.

ABSTRACT: Canine oral malignant melanoma (OMM) is an aggressive, spontaneously occurring tumor carrying a poor to guarded prognosis and relatively limited therapeutic strategies. In this landscape, chondroitin sulfate proteoglycan (CSPG)4 represents a promising immunotherapeutic target. The objective of this bi-center prospective study was to examine the clinical outcome of OMM-bearing dogs treated with surgery and adjuvant electroporation using a DNA vaccine (HuDo-CSPG4) encoding both human (Hu) and canine (Do) portions of CSPG4 through two different vaccination protocols. Dogs with stage I-III surgically resected CSPG4-positive OMM underwent HuDo-CSPG4 plasmid electroporation starting at the 3^rd-4^th post-operative week; electrovaccination was repeated after 2 weeks. In protoc

SUBMITTER: Camerino M 

PROVIDER: S-EPMC11894750 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature